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Abstract
Background: Idiopathic pulmonary fibrosis is a devastating as yet untreatable disease. We demonstrated recently the
predominant role of the NLRP3 inflammasome activation and IL-1b expression in the establishment of pulmonary
inflammation and fibrosis in mice.
Methods: The contribution of IL-23 or IL-17 in pulmonary inflammation and fibrosis was assessed using the bleomycin
model in deficient mice.
Results: We show that bleomycin or IL-1b-induced lung injury leads to increased expression of early IL-23p19, and IL-17A or
IL-17F expression. Early IL-23p19 and IL-17A, but not IL-17F, and IL-17RA signaling are required for inflammatory response to
BLM as shown with gene deficient mice or mice treated with neutralizing antibodies. Using FACS analysis, we show a very
early IL-17A and IL-17F expression by RORct
+ cd T cells and to a lesser extent by CD4ab
+ T cells, but not by iNKT cells, 24 hrs
after BLM administration. Moreover, IL-23p19 and IL-17A expressions or IL-17RA signaling are necessary to pulmonary TGF-
b1 production, collagen deposition and evolution to fibrosis.
Conclusions: Our findings demonstrate the existence of an early IL-1b-IL-23-IL-17A axis leading to pulmonary inflammation
and fibrosis and identify innate IL-23 and IL-17A as interesting drug targets for IL-1b driven lung pathology.
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Introduction
Idiopathic pulmonary fibrosis (IPF) represents a growing health
issue, occurring from repeated lung injury of ill-defined origins.
Patients suffering from this progressive form of interstitial lung
disease present collagen accumulation and localised fibrotic foci in
the absence of overt inflammation. Although chronic in nature,
one complication is an accelerated phase of IPF. These
exacerbations are characterized by acute inflammation reactiva-
tion which is frequently fatal within few weeks to a few months and
underlining the important role of inflammation in IPF evolution
[1]. Using the murine model of bleomycin (BLM)-induced lung
fibrosis, we previously showed that inflammation and fibrosis were
mediated through the pro-inflammatory and pro-fibrotic cytokine
IL-1beta (IL-1b) and IL-1R1/MyD88 signaling in resident cells
[2] [3]. Since interleukin-17 (IL-17) is a major pro-inflammatory
cytokine involved in neutrophil recruitment [4,5] and chronic lung
pathologies [6,7], we hypothesized that IL-1b secreted upon lung
injury may induce innate ‘‘proTh17’’ IL-23 and IL-17 expression
in lung resulting in pulmonary inflammation and evolution to
fibrosis. Interestingly, a crucial role for IL-1 in the induction of IL-
17-producing T cells that mediate autoimmune arthritis or EAE
was reported, suggesting a link between IL-1 and IL-17 in
establishment of some autoimmune diseases [8,9]. IL-1b and IL-
23 were shown to induce innate IL-17 production from cd T cells
amplifying Th17 responses and autoimmunity [10]. More
recently, a study showed that bleomycin and IL-1b-mediated
pulmonary fibrosis was IL-17A dependent [11]. IL-17 was first
described to be produced by a CD4
+ab T cell subset Th17,
characterized by IL-17 (or IL-17A), but also IL-17F, IL-21, IL-22,
IL-6 and TNF-a production [12,13]. The generation of CD4
+
Th17 subset is under the control of specific cytokines and
transcription factors [14]. In mice, TGF-b is necessary and the
switch to the Th17 pathway is induced by IL-6 and/or IL-21 [15]
and requires IL-23 for full in vivo differentiation, expansion and
migration into the circulation and peripheral tissues [16,17].
Similar to IL-17A, IL-17F signals via a receptor complex
composed with IL-17RA and IL-17RC. The relative contribution
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also shown to be produced very early by cd T cells triggering
protective immunity against infection [18] exacerbating chronic
inflammation [19]. During an immune response, cd T cells rapidly
produce IL-17 in response to IL-23 and/or other dendritic cell
products while antigen-specific CD4
+ab
+ Th17 cells develop later
[20,21]. Recently NKT cells that lack the NK1.1 marker were also
identified as early IL-17-producing cells that can contribute to
neutrophil recruitment through IL-17 secretion [22]. IL-17
synthesis depends on the RORct transcription factor in both IL-
17 producing CD4
+ab Th17 cells, and cd T cells but also iNKT17
cells [23,24,25].
Here, we addressed the respective role of IL-17A and F, and the
cellular source and activation cascade in response to BLM-induced
airway injury. We show that lung injury triggers the expression of
early IL-23, IL-17A and IL-17F in an IL-1 dependent manner,
that early IL-23 and IL-17A, but not IL-17F are necessary for the
establishment of the innate response to BLM and that cd T cells
are the major source of early IL-17A and IL-17F. Moreover, IL-
23p19 is required for the late evolution to pulmonary fibrosis.
Importantly, IL-23p19 and IL-17A are upstream of the expression
of TGF-b1 the central mediator of lung fibrosis suggesting that
innate IL-17A from cd T cells [26] might promote the
commitment towards an inflammatory Th17 phenotype through
induction of TGF-b1 in an IL-6 rich environment.
Methods
Mice
IL-1R12/2 [27], IL-23/p192/2 [28] and IL-17RA2/2
[29] backcrossed 10 times on the wild-type C57BL/6 genetic
background were bred in our animal facility at the Transgenose
Institute (CNRS, Orleans). Rorc(ct)-Gfp
TG were used for IL-17
producing cells investigation [30]. All animal experiments
complied with the French Government’s ethical and animal
experiment regulations. This protocole was analysed and ap-
proved under the number CL2007-033 by the Ethic commitee for
animal experimentation of CNRS and University in Orleans.
Treatments
Bleomycin sulfate (5, 7.5 or 10 mg/kg) from Bellon Laborato-
ries (Montrouge, France), rmIL-1b (50 mg/kg) from R&D Systems
(Minneapolis, USA) were given intranasally in 40 mL under light
ketamine-xylasine anesthesia. IL-17A (100 mg, Novartis Pharma,
Basel, Switzerland), IL-17F (100–150 mg, Dr C. Uyttenhove,
Bruxelles, Bergium) neutralizing antibodies or control Ig were
administered intranasally or intraperitonally. A dose-response
study was performed to find the effective dose for both antibodies.
Bronchoalveolar Lavage Fluid (BALF)
BALF was performed as previously described [3].
Lung homogenization and analysis
Lungs were homogenized and lung tissue myeloperoxidase
activity (MPO) was evaluated as described [3].
Cell count and determination
Total cell and differential cell counts were determined in BALF
as previously described [3].
Mediator measurements by ELISA
IL-1b, KC, IL-6 and TIMP-1 levels in BALF or lung
homogenate were determined by ELISA (R&D system, Minne-
apolis, USA). Latent or active TGF-b1 levels were assayed in
BALF and lung homogenates by ELISA (R&D, Minneapolis,
USA). Latent or active TGFb-1 was not detected in lung
homogenates using this method.
Semi-quantitative PCR
IL-17A, IL-17F, IL-23/p19 or IL-1b mRNA levels in lung were
assessed (Online supplemented material). The electrophoresis gels
were analyzed using a densitometric analyzer (ImageJ). Band
densities were measured and compared to housekeeping gene
HPRT1.
Zymographic analysis of MMPs
MMP-2 activity was determined by gelatin zymography as
described [2].
Histology
After BAL and lung perfusion, the large lobe was fixed and 3-
mm sections were stained with Hematoxylin and Eosine (H&E) or
sirius red. For collagen determination the slides were stained with
0.1% picrosirius solution (0.1% sirius red in satured aqueous picric
acid, pH 2) for 1 h, counterstained with Mayer’s hematoxylin for
2 min. All the slides were numerised with Nikon i80 – X10 plan
APO objective and QICAM color cooling camera (Qimaging).
The lung sections were analyzed by imageJ - NIH software. The
percentage of collagen was determined.
Total lung collagen assay
Aliquots of lung homogenate (50 ml) were assayed for total lung
collagen levels using the Sircol collagen dye binding assay
according to the manufacturer’s instructions (Biocolor Ltd,
Northern Ireland).
Flow cytometry analysis
Lung mononuclear cells were isolated and stimulated in the
Online supplemented material. Cells were incubated with
CD1d-tetramer-APC (NHI tetramer), anti-NK1.1-PerCP-
Cy5.5, anti-CD4-APCalexa750, anti-CD8-PB, anti-TCRcd-
APC, anti-TCRab-APC, anti-CD11bPerCp Cy5.5 (BD Phar-
Mingen) or isotype control antibodies. For intracellular staining,
cells were fixed with 4% PFA, washed, and permeabilized with
0 . 5 %s a p o n i n( S i g m a - A l d r i c h )i nP B S ,t h e ni n c u b a t e dw i t ha n t i -
IL-17A-PE, anti-IL-17F-PE, anti-GFP alexa488, anti-IL12p40-
FITC anti-IL-23p19-alexa647 or isotype controls. The cells
were analyzed in a FACSCanto II (Becton Dickinson) by using
FlowJo software.
Statistical Analysis
Statistical evaluation of differences between the experimental
groups was determined by non parametric one way analyse of
variance test and Bonferroni post test using Prism software. P
values of ,0.05 were considered statistically significant.
Results
Early IL-23p19, IL-17A and IL-17F expression after airway
bleomycin or IL-1b administration
We previously showed that inflammation, remodeling and
fibrosis after bleomycin (BLM) exposure were mediated through
IL-1b release with recombinant murine IL-1b (rmIL-1b) recapit-
ulating the effects of BLM [2]. We speculated that IL-1b secreted
upon lung injury may induce innate IL-23 and IL-17 expression in
lung resulting in pulmonary inflammation and evolution to
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PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23185Figure 1. IL-23p19, IL-17A or IL-17F expression upon BLM or rmIL-1b. mRNA expression for IL-23p19, Pro-IL-1b and HPRT1 in lung of 4
individual mice treated with BLM (10 mg/kg) or rmIL-1b (50 mg/kg) or saline were assessed using semi-quantitative PCR at 24 h in wild-type mice (A).
Semi-quantitative IL-1b expression in the lung, evaluated with IL-1b/HPRT1 PCR ratio, was reduced in absence of IL-23p19 signaling (B). mRNA
expression for IL-17A, IL-17F and HPRT1 in lung of 5 individual mice treated with BLM (10 mg/kg) or rmIL-1b (50 mg/kg) or saline wild-type mice or IL-
1R12/2 mice were assessed using semi-quantitative PCR at 24 h (C). IL-17A and IL-17F mRNA levels were compared to the housekeeping gene HPRT1
mRNA levels and expressed as IL-17/HPRT ratio by measuring band densities using a densitometric analyzer (ImageJ) (D). Data represent in FiguremRNA
expression Data represent mean values 6 SD from 3 ratio independent experiments (n=4 or 5 mice per group; *, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0023185.g001
Figure 2. Acute inflammation and remodeling upon BLM are dependent on IL-23p19. Analysis of acute inflammation and remodeling was
performed 24 h after BLM instillation (7.5 mg/kg). IL-23p19 deficient mice showed reduced neutrophil recruitment in BALF (A) and lung tissue (B) and
reduced TIMP-1 production in lung (c) in comparison to wild-type mice Data represent mean values 6 SD from 2 independent experiments (n=5
mice per group; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0023185.g002
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lung upon local BLM or rmIL-1b. Using semi-quantitative PCR
analysis, we showed that IL-23/p19 mRNA expression is
increased in lung of wild-type mice, 24 h after a single
intranasal administration of BLM (Fig. 1A). Since IL-1b is
induced following BLM, we asked whether rmIL-1b could also
cause IL-23p19 expression. Indeed, instillation of rmIL-1b
induced a significant increase of IL-23p19 pulmonary mRNA
expression (Fig. 1A, B). Moreover BLM-induced pro-IL-1b
expression in the lung was not affected in absence of IL-23p19
indicating that IL-1b is upstream of IL-23p19 (Fig. 1A, B).
These results suggest that IL-1b produced locally upon lung
injury induce IL-23p19 expression in the lung. Intracellular
staining of IL-23p19
+ cells by flow cytometry confirmed that IL-
23p19 is produced by lung infiltrating CD11b
+ monocytes (not
shown). We then analyzed the respective expression of IL-17A
and IL-17F in the lung after local BLM or rmIL-1b
administration. We showed that IL-17A but not IL-17F mRNA
expression is induced in the lung 24 h after BLM in these
experimental conditions (Fig. 1C, D). Instillation of rmIL-1b
induced a dramatic increase of IL-17A and IL-17F pulmonary
mRNA expression (Fig. 1C, D). IL-17A and F expression after
local BLM in IL-1R1 deficient mice was reduced in absence of
I L - 1 R 1s i g n a l i n gs u g g e s t i n gt h a tI L - 1 b produced locally upon
lung injury may in turn induce IL-17A and IL-17F expression in
t h el u n g( F i g .1 C ,D ) .T h e s ed a t as h o wt h ee x i s t e n c eo fa nI L -
1b-IL-23-IL-17A axis following lung injury.
Early pulmonary inflammation is dependent on IL-23p19
and IL-17RA signaling
To investigate whether IL-23p19 plays a role in lung
inflammation upon lung injury, we evaluated early airway
inflammatory cell response after airway BLM administration in
lung of IL-23p19 deficient mice. Within 24 h, BLM elicited an
acute neutrophil recruitment into the bronchoalveolar lavage fluid
(BALF) and into the lung in C57BL/6 wild-type mice (Fig. 2A, B).
In the absence of IL-23p19, neutrophil recruitment in the BALF
(Fig. 2A) and neutrophil activity in the lung as assessed by MPO
activity measurement (Fig. 2B) were dramatically reduced. Saline
administration did not cause neutrophil influx in either group. IL-
6 and KC production in lung 24 h after BLM were also
diminished in the absence of IL-23p19 but IL-1b release was
unaffected (not shown). To evaluate the role of IL-23p19 in the
possible protease/antiprotease imbalance, we measured tissue
inhibitor of matrix metalloproteinase-1 (TIMP-1) levels into the
lung after BLM administration. Production of TIMP-1 is the
hallmark of evolution towards fibrosis. Twenty four hours after
BLM administration, lung TIMP-1 was significantly increased in
wild-type mice but not in IL-23p19 deficient mice (Fig. 2C). Thus,
BLM induced airway neutrophil recruitment, KC, IL-6 and
TIMP-1 expression in an IL-23p19 dependent way, while IL-1b
release was likely upstream of IL-23. To assess whether innate IL-
17A and/or IL-17F play a role in early lung inflammation, we
evaluated the inflammatory cell response in the lung of mice
deficient for IL-17 receptor (IL-17RA). In the absence of IL-
Figure 3. Impaired acute lung inflammation upon BLM in IL-17RA deficient mice. IL-17RA deficient mice showed reduced neutrophil
recruitment in BALF (A) and lung tissue (B) in comparison to wild-type mice. BALs and myeloperoxidase (MPO) activity were performed 24 h after BLM
instillation (7.5 mg/kg). KC (D), IL-6 (E) and TIMP-1 (F) levels in the lung were also reduced in IL-17RA deficient mice at 24 h but not IL-1b levels (C).
Cytokines, chemokine and TIMP-1 quantification in lung homogenates were performed by ELISA. Data represent mean values 6 SD from 4
independent experiments (n=5 mice per group; ns, not significant, *, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0023185.g003
Lung Injury Depends on IL-17 and IL-23
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e2318517RA, neutrophil recruitment in the BALF (Fig. 3A) and
neutrophil activity in lung (Fig. 3B) were dramatically reduced
24 h post BLM. Production of both KC (Fig. 3D) and IL-6
(Fig. 3E) in the lung were reduced in IL-17RA deficient mice but
IL-1b levels were not significantly modified, indicating that IL-1b
is upstream of IL-17 (Fig. 3C). Moreover 24 h after BLM
administration, lung TIMP-1 expression was induced in wild-type
mice but not in IL-17RA deficient mice (Fig. 3F). Thus, BLM
induced airway neutrophil recruitment, KC, IL-6 and TIMP-1
expression in an IL-17RA dependent way, while IL-1b release was
likely upstream of IL-17.
IL-17A, but not IL-17F, is essential for bleomycin-induced
acute lung inflammation and remodeling
To determine the relative contribution of IL-17A and IL-17F in
BLM-induced acute lung inflammation, we investigated the
inflammatory response to BLM using neutralizing antibodies
against IL-17A or IL-17F. Neutralization of IL-17A led to a
significant reduction of neutrophil recruitment into the BALF
(Fig. 4A) and reduction of neutrophil MPO activity in the lung
(Fig. 4B) 24 h after BLM administration. IL-1b (Fig. 4C), KC
(Fig. 4D), IL-6 (Fig. 4E) or TIMP-1 (Fig. 4F) lung levels were also
reduced after IL-17A neutralization. Lower IL-1b in mice treated
with anti-IL17A could be explained by the existence of an
autocrine or paracrine loop with IL-17 inducing IL-1b production
and amplifying the response. In contrast, we could exclude a role
of IL-17F in these responses by analyzing the effect of IL-17F
neutralizing antibodies. Blocking IL-17F had no significant effect
on neutrophil recruitment into the BALF (Fig. 5A) or into the lung
parenchyma as shown by MPO analysis (Fig. 5B). Pro-inflamma-
tory cytokines and chemokine levels were also not reduced by IL-
17F neutralizing antibodies (Fig. 5C–E). Moreover, anti-IL-17F
antibodies had no effect on lung TIMP-1 levels (Fig. 5F). Anti-IL-
17A and anti-IL-17F antibodies were used at doses efficient in
blocking lung neutrophilic inflammation induced by intranasal
administration of rmIL-17A or rmIL-17F, respectively, to C57BL/
6 wild-type mice (data not shown). Therefore, locally BLM-
induced inflammation, but also repair processes depend on
functional IL-17A, but not on IL-17.
Cellular source of early IL-17A and F: cd and ab T cells but
not iNKTcells
In order to investigate the IL-17 producing cells in the lung in
response to bleomycin administration, we used transgenic Rorc(ct)-
Gfp
TG mice expressing EGFP under control of the Rorc(ct)
promoter on a bacterial artificial chromosome (BAC) which allows
visualization of the RORct
+ cells [24]. RORct was shown to be a
marker for IL-17–producing cells in both ab and cd T cell
populations [24]. Lymphocytes from the lung of Rorc(ct)-Gfp
TG
mice were collected 24 h after BLM or saline administration,
stimulated in vitro with PMA/ionomycin, and cell surface markers
and intracellular staining for IL-17 were performed. FACS
analysis showed that BLM administration enhanced the total
number of IL-17A
posRORct
pos and IL-17F
posRORct
pos lung
Figure 4. Acute lung inflammation and remodeling upon BLM depends on IL-17A. Inflammatory and remodeling responses of wild-type
mice treated with neutralizing antibody against IL-17A (150 mg/mouse, i.p. just after BLM or saline i.n. instillation). Neutrophil recruitment in BALF (A)
and myeloperoxidase (MPO) activity in lung tissue (B) induced by BLM (7.5 mg/kg) were reduced after mice treatment with anti-IL-17A. IL-1b (C), KC
(D), IL-6 (E) and TIMP-1 (F) levels in lung homogenates assessed by ELISA were also reduced 24 h after mice treatment neutralizing antibody against
IL-17A. Data represent mean values 6 SD from 3 independent experiments (n=4 mice per group; *, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0023185.g004
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for RORct were essentially cd T cells and CD4
posab T cells but
few iNKT cells (Fig. 6B). Up to 70% of IL-17A
posRORct
pos cells
and 60% of IL-17F
posRORct
pos were cd T cells. Among cd T cells
recruited after BLM administration, more than 30% produce IL-
17A and 5% produce IL-17F (Fig. 6C). These data demonstrate
that early IL-17A and F producing cells in response to BLM-
induced lung injury are essentially cd T cells and to a lesser extent
CD4
posab T cells, while almost no iNKT cells produced IL-17A or
F in these conditions.
Lung remodeling and fibrosis are dependent on IL-23
To further assesss the role of IL-23 in lung fibrosis we analyzed
remodeling and fibrosis in lungs of IL-23p19 deficient mice 14
days after BLM administration. MMP-2 (or gelatinase A, 72 kDa)
is well described in pulmonary fibrosis, preferentially secreted by
fibroblasts and epithelial cells [31]. Assessing gelatinase activity by
zymography, we showed that BLM dramatically induced MMP-2
activity in wild-type mice and this activity was significantly
reduced in IL-23p19 deficient mice (Fig. 7A). Moreover, BLM-
induced TIMP-1 expression was also reduced in IL-23p19
deficient mice (Fig. 7B). Since TGF-b1 is essential in the
development of lung fibrosis and also in the development of IL-
17 producing cells in particular Th17 cells, we asked whether the
production of TGF-b1 upon bleomycin is dependent on IL-23.
Indeed, latent TGF-b1 was detected after activation in BALF from
wild-type mice, 14 days after bleomycin administration but was
reduced in BALF from IL-23p19 deficient (Fig. 7C). Active TGF-
b1 was undetectable in BALF from wild-type and deficient mice
probably due to lower production (data not shown). Microscopic
analysis of lung sections showed extensive fibrotic areas with
abundant collagen deposition as compared to normal alveolar
structure of the saline controls 14 days post BLM. Cellular
infiltrates, alveolar wall destruction and collagen deposition were
Figure 5. Acute lung inflammation and remodeling upon BLM are independent of IL-17F. Inflammatory and remodeling responses upon
BLM (7.5 mg/kg) of wild-type mice treated with neutralizing antibody against IL-17F (100–150 mg/mouse, i.p. just after BLM or saline i.n. instillation).
Neutrophil recruitment in BALF (A) and myeloperoxidase (MPO) activity (B) upon BLM (7.5 mg/kg) were not reduced 24 h after treatment with high
doses of neutralizing antibody against IL-17F. IL-1b (C), KC (D), IL-6 (E) and TIMP-1 (F) in lung homogenates assessed by ELISA were also reduced in
BLM mice 24 h after treatment with neutralizing antibody against IL-17F. Treatments with anti-IL-17F had not significant effect on all these
parameters. Data represent mean values 6 SD from 2 independent experiments (n=6 mice per group).
doi:10.1371/journal.pone.0023185.g005
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comparison to BLM-treated wild-type mice. Collagen quantifica-
tion in lung homogenates showed that total collagen content,
enhanced 14 days after bleomycin instillation was significantly
reduced in lung of IL-17RA deficient mice (Fig. 7D). These data
demonstrate that lung remodeling and fibrosis require IL-23 for full
responses in vivo and that IL-23 is involved in TGF-b1 production in
response to epithelial lung injury induced by bleomycin.
Figure 6. Early IL-17A and F are produced mainly by cd T cells. Lymphocytes from the lung of Rorc(ct)-Gfp
TG mice were prepared 24 h after
BLM or saline administration, and stimulated in vitro with PMA/ionomycin for 4 h. Specific staining of cell markers (CD1d-tetramer-APC, anti-NK1.1-
PerCP-Cy5.5, anti-CD4-APCalexa750, anti-CD8-PB, anti-TCRcd-APC, anti-TCRab-APC), or isotype control and intracellular staining for IL-17 (anti-IL-17A-
PE, anti-IL-17F-PE, anti-GFP alexa488 or isotype controls) were performed. FACS analysis showed that BLM administration enhanced the total number
of IL-17A
posRORct
pos and IL-17F
posRORct
pos lung mononuclear cells (A). IL-17-producing cells positive for RORct were essentially cd T cells and CD4
pos
ab T cells but few iNKT cells (B). Among cd T cells after bleomycin administration, at least 30% produce IL-17A and 5% produce IL-17F (C). Results are
mean values 6 SD from 4 independent experiments, with pools of 5 mice/group for each experiment, * p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0023185.g006
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are reduced in the absence of IL-17RA signaling and can
be prevented by IL-17A neutralization
Furthermore, the analysis of remodeling in lung of IL-17RA
deficient mice 14 days after BLM administration showed that
MMP-2 activity and TIMP-1 level were reduced (Fig. 8A, B). As
latent TGF-b1 was reduced in BALF from IL-23-p19 deficient
mice, we asked whether it required functional IL-17A. Latent
TGF-b1 expression was also reduced in IL-17RA deficient mice
(Fig. 8C) whereas active TGF-b1 remained undetectable (data not
shown). Total collagen content in lung was significantly reduced in
IL-17RA deficient mice in comparision to wild-type mice (Fig. 8D).
Moreover, we observed that cellular infiltrates, alveolar wall
destruction and collagen deposition were significantly reduced in
IL-17RA deficient (Fig. 8E) in comparison to BLM-treated wild-
type mice.
We further confirmed the implication of IL-17A in lung
remodeling, and demonstrate that these developments can be
prevented by anti-IL-17A neutralizing antibodies. Antibodies to
IL-17A administered after BLM reduced MMP-2 activity in
BALF (Fig. 9A), TIMP-1 level in lung (Fig. 9B) and latent TGF-
b1 level in BALF (Fig. 9C) in wild-type mice. Moreover, anti-IL-
17A antibody treatment attenuated pulmonary fibrosis observed
at day 14 (Fig. 9E). Remodeling response, analyzed by collagen
specific sirius red staining of microscopic lung sections showed
that lung collagen content, enhanced after BLM, was signifi-
cantly reduced by anti-IL-17A antibody treatment (Fig. 9D).
Therefore, IL-17A and IL-17RA signaling are required for the
development of pulmonary inflammation, fibrosis, and collagen
deposition in response to bleomycin and IL-17A neutralization
can prevent evolution towards fibrosis.
Discussion
In this study, we report the involvement of IL-23p19 and innate
IL-17A in the occurrence of pulmonary inflammation and fibrosis
and demonstrate the critical role of IL-1b in these processes. We
show the existence of an IL-1b/IL-23/IL-17 axis which is essential
for bleomycin-induced pulmonary inflammation, remodeling and
fibrosis. While this study was being finalized, Wilson and
colleagues published a study reporting a critical role for IL-17A
in BLM- or IL-1b-induced lung fibrosis [11].
IL-23p19 and IL-17A were expressed early in tissue following
local bleomycin suggesting that these cytokines play a role in lung
injury-induced inflammation and subsequent evolution to fibrosis.
Wilson et al showed a weak IL-17A protein expression after
restimulation of BAL and lung cells at day 4 and day 7 post BLM
administration, respectively followed by a high IL-17A expression
on day 7, 14 and 21 after bleomycin [11]. We previously outlined
that exogenous IL-1b can mimic the BLM-induced pathology [2]
and this was confirmed by Wilson et al [11]. We analyzed the
effect of airway rmIL-1b on pulmonary IL-23p19 and IL-17
expression. IL-23p19, IL-17A and IL-17F mRNA were strongly
increased after airway rmIL-1b administration and bleomycin-
induced IL-17A and IL-17F expression were dependent on IL-
1R1 signaling, demonstrating that IL-1b is upstream of IL-17.
Further, IL-17 may promote IL-1b production by an amplification
loop. Therefore the data suggest that lung injury promotes IL-1b
production which increases IL-23 expression and in turn can
stimulate innate IL-17 expression. An IL-1b/IL-17 axis has been
reported in experimental autoimmune encephalomyelitis and
arthritis for which a crucial role for IL-1b in the induction of
IL-17-producing T cells was demonstrated [9,10,32]. Moreover
IL-1b drives pathogenic Th17 cells during spontaneous arthritis in
Figure 7. Remodeling and fibrosis are dependent on IL-23p19. Analysis of late pulmonary remodeling and fibrosis was performed 14 days
after BLM administration (5 mg/kg). MMP-2 activity (A) and TIMP-1 production (B) were reduced in IL-23p19 deficient mice. Active MMP-2 was
expressed as relative intensity (RI). Latent TGF-b1 detected in BALF from wild-type mice was reduced in BALF from IL-23p19 deficient mice (C). Total
collagen content in lung was significantly reduced in IL-23p19 deficient mice in comparision to wild-type mice (D). Collagen was measured using the
Sircol collagen dye binding assay. Lung microscopic sections showed extensive fibrotic areas with collagen deposition in wild-type mice treated with
BLM which was attenuated in IL-23p192/2 mice (e). Sirius red (SR) staining, scale bars 1 mm and 200 mm, n=5 mice. Data represent mean values 6
SD from 2 independent experiments (n=5 mice per group; *, p,0.05; **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0023185.g007
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destructive arthritis was reduced in IL-17RA deficient mice
whereas abolished in IL-1R1 deficient mice [34]. In multiple
sclerosis, IL-17 was produced by microglia in response to IL-23 or
IL-1b [35]. In mice, IL-1b and IL-23 are produced by dendritic
cells upon infection-induced Th-17 cells [36]. After lung injury,
IL-1b may be produced very early by dendritic cells and alveolar
macrophages acting on IL-17 producing cells to promote IL-17
expression. Our study showed for the first time that early IL-23p19
and IL-17RA signaling were necessary to trigger pulmonary
inflammation and remodeling responses in response to lung injury.
We confirmed the role of IL-17A in these responses [11].
Furthermore, we document the relative role of IL-17A versus
IL-17F in lung inflammation leading to fibrosis, an aspect not
known before [37]. We showed that IL-17A promotes pulmonary
inflammation and remodeling upon airway BLM whereas IL-17F
has no effect. IL-17A and IL-17F which are highly homologous
members of the IL-17 protein family and bind the same receptor
complex consisting of IL-17RA and IL-17RC were often described
as pro-inflammatory cytokines with redundant role in inflamma-
tion and autoimmunity. IL-17F apparently plays a marginal role in
the development of delayed-type and contact hypersensitivities,
autoimmune encephalomyelitis, collagen-induced arthritis, and
arthritis in IL-1Ra deficient mice. In asthma, IL-17F may play an
important regulatory role and seems to function differently than
IL-17A [37,38]. Our results suggest that unlike IL-17A, IL-17F
has no essential role in acute inflammation in our model.
Overlapping or distinct roles of these cytokines may depend on
IL-17A and/or IL-17F production by different cell types or on the
role of functional homodimers or heterodimers. Since the role of
innate IL-17 is less known and in an attempt to identify the cells
producing IL-17 very early, we found cd T cells but neither iNKT
cells nor ab T cells as the major source of innate IL-17A and IL-
17F, 24 hrs after induction of lung injury. IL-17-producing cd T
cell were present in naı ¨ve mice and enhanced after bleomycin.
Indeed, IL-17- producing cd T cells may be differentiated in the
periphery and poised ready to produce IL-17 in a rapid manner
[39]. This is the first demonstration of early IL-17A and F
production by cd T cell after pulmonary injury. IL-17A producing
cd T cells are more present than IL-17F producing cd T cells in
agreement with the predominant role of IL-17A in pulmonary
inflammation after injury. Late pulmonary induction of IL-17
expression by cd T cells 7 and 14 days after local bleomycin was
reported but the direct role of the IL-17 on late inflammation and
fibrosis was not studied [6]. Moreover, in this study deletion of all
cd T cell was associated with reduced inflammation in the
bronchoalveolar space but severe interstitial inflammation with
complete loss of alveolar structure and delayed epithelium repair 7
and 14 days after bleomycin. By contrast, using mice deficient for
IL-17 signaling or treated with anti-IL-17 antibodies, we show
reduced inflammation in the bronchoalveolar space and in
interstitium inflammation and confirmed two studies reporting
that IL-17 has a detrimental role in lung fibrosis [6,11]. Dendritic
epidermal cd T cells involved in skin epithelium wound repair [40]
Figure 8. Attenuation of bleomycin-induced lung fibrosis in IL-17RA2/2 mice. Pulmonary remodeling and fibrotic response of wild-type
mice or IL-17RA deficient mice 14 days after BLM or saline i.n. instillation. MMP-2 (72 Kd) activity in BALF was analyzed by zymography 14 days after
administration of BLM (5 mg/kg i.n.). Active MMP-2 was upregulated at day 14 after BLM in the BALF of wild-type mice but only partially in
IL-17RA2/2 mice (A). TIMP-1 as indicator of a fibrotic process was upregulated in the lungs of B6, but to a lesser extent in IL-17RA2/2 mice on day
14 (B). The latent form of TGF-b1 was present in BALF from B6 mice, 14 days after BLM, but was reduced in BALF from IL-17RA deficient mice as
determined by ELISA assay (C). Active MMP-2 was expressed as relative intensity (RI). TIMP-1 and TGF-b1 levels were assessed by ELISA. Total collagen
content enhanced 14 days after bleomycin instillation was significantly reduced in lung of IL-17RA deficient mice (D). Collagen was measured using
the Sircol collagen dye binding assay. Data represent mean values 6 SD from 2 independent experiments (n=4 mice per group; *, p,0.05;
**, p,0.01; ***p,0.001). Lung microscopic sections showed extensive fibrotic areas at day 14 with collagen deposition in wild-type mice treated with
BLM (5 mg/kg i.n.) which was attenuated in IL-17RA2/2 mice (E). Sirius red (SR) staining, scale bars 1 mm and 200 mm, n=5 mice).
doi:10.1371/journal.pone.0023185.g008
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lung of tobacco smokers without COPD [41]. Depletion of these
cells might be responsible for the disease aggravation described in
cd deficient mice [6]. Dendritic epidermal cd T cells with lung
wound repair activity and IL-17 producing cd T cells with
detrimental effect may coexist in the airways after lung injury. This
could explain the different phenotypes observed between our study
with mice deficient for IL-17 signaling and Braun and collagues’s
study with mice deficient for cd T cells. As we show that early IL-
17 producing cells are essentially cd T cells, this suggests that IL-
17 producing cd T cells have a detrimental effect probably in
inducing the expansion of Th17 which are auto-reactive and
pathogenic T cells. cd T cells were described as non-conventional
T-cell implicated in early innate immunity whereas conventional
CD4 ab Th17 cells were often involved in adaptive immunity
suggesting that late IL-17 producing cells in response to
bleomycin-induced lung damages would be CD4 ab Th17 cells
[21]. In support of this, it was shown that IL-17-producing cd T
cells activated by IL-1b and IL-23 can promote IL-17 production
by CD4
+ T cells suggesting that cd T cells act in an amplification
loop for IL-17 production by Th17 cells [10]. Even if IL-17
production by cd T cells has a protective role in inducing adaptive
immune response against infection, IL-17 producing cd T cells
were implicated in inflammatory diseases associated with tissue
damage [42,43] and in the generation and activation of IL-17-
producing auto-reactive T cells. IL-17-producing cd T cells
exacerbate collagen-induced arthritis and experimental autoim-
mune encephalomyelitis (EAE) [10].
Interestingly we report that airway TGF-b1, the main critical
mediator of remodeling and fibrotic responses in the lung, was
induced after lung injury in wild-type mice but strongly reduced in
IL-23p19 and IL-17RA deficient mice or wild-type mice treated
with anti-IL-17A antibodies indicating that IL-23p19 and IL-17A
are upstream of the expression of TGF-b1 and suggesting that
innate IL-17A produced by cd T lymphocytes may influence the
production of TGF-b1. In case of repeated injury, the emergence
of TGF-b1 as a component associated with cellular injury and
inflammation with IL-6 and IL-1b would provide the conditions
for differentiation of CD4 ab Th17 cells as a second wave of
immune response. Wilson et al reported that IL-17A-induced
fibrosis depend on TGF-b1. This may be explained by the
existence of an amplification loop, early IL-17A inducing TGF-b1
and TGF-b1-dependent production of late IL-17A. Moreover, we
showed for the first time that IL-23 is required for full
establishment of pulmonary inflammation, remodeling and fibrosis
in mice. IL-12p40 subunit, which associates with IL-23p19 subunit
to form IL-23 cytokine, but neither IL-12p35 nor IL-12p70, was
shown to play a key role in silica-induced pulmonary inflammation
and fibrosis [44]. Increased serum IL-23 was observed in patients
with systemic sclerosis [45]. Our results strongly support the
Figure 9. Attenuation of bleomycin-induced lung fibrosis upon anti-IL-17A treatment. Pulmonary remodeling and fibrotic responses of
wild-type mice treated with neutralizing antibody against IL-17A (150 mg/mouse, i.p. just after BLM and 3 times per week) 14 days after BLM (5 mg/kg
i.n.) or saline. MMP-2 (72 Kd) activity in BALF was analyzed by zymography 14 days after administration of BLM. Active MMP-2 upregulated upon BLM
in the BALF of wild-type mice was greatly reduced after 6 treatments with neutralizing antibody against IL-17A (A). TIMP-1 in lung was also
significantly decreased after treatment with neutralizing antibody against IL-17A in comparison to untreated BLM mice (B). Latent TGF-b1 detected in
BALF from wild-type mice was reduced in BALF from wild-type mice treated with anti-IL-17A antibodies (C). Active MMP-2 was expressed as relative
intensity (RI). TIMP-1 and TGF-b1 levels were assessed by ELISA. In order to quantify lung collagen deposition, all the slides were numerised by
Qimaging and analyzed by imageJ - NIH software. % of SR by lung were shown. Collagen content enhanced after BLM was significantly reduced when
the mice were treated with anti-IL-17A antibody (D). Data represent mean values 6 SD from 2 independent experiments (n=5 mice per group;
*, p,0.05; ***, p,0.001). Lung microscopic sections showed extensive fibrotic areas at day 14 with collagen deposition in wild-type mice
administrated with BLM which was attenuated in mice treated with neutralizing antibodies against IL-17A (E). Sirius red (SR) staining, scale bars 1 mm
and 200 mm, n=5 mice.
doi:10.1371/journal.pone.0023185.g009
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response to epithelial cell damage. Naı ¨ve cd T cells have been
shown to produce IL-17 in response to IL-23 alone [18,39] and to
constitutively express IL-23 receptor [10,46]. These cells have a
pathogenic role in severe disease such as collagen-induced arthritis
[19]. In this case they appear to be driven by self molecules that
arise during inflammation. Such a break of self tolerance with
induction of pathogenic IL-17 producing cd T cells should be
possible in the case of repeated lung injury and inflammation
leading to pulmonary fibrosis. Our study showed for the first time
that IL-23p19 and IL-17RA signaling were necessary to trigger
late pulmonary inflammation and fibrosis and confirmed by IL-
17A neutralization that IL-17A is required for late disease [11].
Wilson’s study and our work are largely in agreement or
complementary although minor discrepancies may be due to the
use of two different sources of bleomycin [11]. Another study
described how IL-17A may regulate the expression and/or
proinflammatory properties of IL-22 in pulmonary fibrosis but
did bot analysed the link between IL-1b, IL-23and IL-17 [47].
In conclusion, we highlighted the existence of an innate IL-1b-
IL-23-IL-17A axis in the establishment of early pulmonary
inflammation with direct consequences on late evolution to fibrosis
after lung injury. We demonstrate that IL-23p19, IL-17A and IL-
17RA signaling are essential to pulmonary inflammation whereas
IL-17F seems dispensable. Moreover we identified cd T cells as the
major source of early IL-17A, providing a new mechanism
whereby IL-1 and IL-23 may mediate pulmonary fibrosis. IL-
23p19 was identified for the first time as an essential mediator of
pulmonary fibrosis. Importantly, IL-23p19 and IL-17A are
upstream of TGF-b1 the central mediator of lung fibrosis. Our
findings point on the potential role of IL-17-producing TCRcd T
cells in lung injury as a first line of defense that can orchestrate an
inflammatory response leading to pulmonary fibrosis. Our study
provides new information on the pathogenic role of IL-23 and IL-
17 underlining the importance of targeting these cytokines in the
development of new therapeutic approaches against lung fibrosis.
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